PAR-21-114: NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Pre-Clinical Research (R44 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2021.
National Institutes of Health offered grants to small businesses. Applications closed on April 5, 2024.
From the official notice on Grants.gov, last changed January 5, 2024. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR44
- Clinical trialsNot allowed
- Funded byNINDS
- Median yearly award$978,397
- Typical project length5 years
- R44, Small Business Innovation Research (SBIR) Phase II. Full research and development of an SBIR project after Phase I (or both phases at once, called Fast Track). Other open R44 notices.
Projects funded under PAR-21-114 were run by National Institute of Neurological Disorders and Stroke (NINDS, 5 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read PAR-21-114 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| PAR-24-222 | June 21, 2024 | Closed November 17, 2025 | Closed |
Key dates
| Posted | January 25, 2021 |
|---|---|
| Deadline | April 5, 2024 |
| Archived by Grants.gov | May 5, 2024 |
Who can apply
This opportunity was open to small businesses.
- Small businesses
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Is this a realistic fit?
- Most of the program's money (76% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
Some projects initiated with SBIR or STTR funding require considerable financing beyond the SBIR/STTR Phase II award to achieve commercialization. The development of medical biotechnology products is often impeded by a significant funding gap (known as the Valley of Death) between the end of the SBIR/STTR Phase II award and the commercialization stage. The goal of this FOA is to assist applicants in pursuing the next appropriate milestone(s) necessary to advance a product/technology that requires Federal regulatory approval or to bring a complex research tool to market. This opportunity aims to facilitate the transition of previously funded SBIR and STTR Phase II projects to the commercialization stage by promoting partnerships between NINDS SBIR or STTR awardees and third-party investors and/or strategic partners in the Phase IIB competing renewal. Applicants are strongly encouraged to secure independent third-party funding throughout the Phase IIB project period.
Funded under PAR-21-114 so far
NIH funded 5 projects under PAR-21-114 in fiscal 2022 to 2026, at 5 institutions. The median yearly award was $978,397.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Line extension and expanded preclinical evidence for Nerve Tape, a sutureless nerve repair coaptation device | Biocircuit Technologies, Inc. | 2026 | $777,562 |
| Further assessment of durability of a gene editing therapy for Duchenne muscular dystrophy | Myogene Bio, LLC | 2026 | $978,397 |
| Targeted DOK7 gene therapy for Congenital Myasthenic Syndromes | Amplo Biotechnology, Inc. | 2024 | $3.0 million |
| Ultra-High-Throughput Plate Reader for Drug Discovery Using All-Optical Electrophysiology | Quiver Bioscience Inc. | 2024 | $251,085 |
| Inter-alpha Inhibitors in Hypoxic-Ischemic Brain Injury | Prothera Biologics, LLC | 2023 | $2.8 million |
Who has won Extramural Research Programs in the Neurosciences and Neurological Disorders grants before
From fiscal 2021 to 2025, Extramural Research Programs in the Neurosciences and Neurological Disorders (93.853) awarded $9.1 billion across 8,641 grant awards, an average of $1.0 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The General Hospital Corporation | Massachusetts | 203 | $288 million |
| The Regents of the University of California, San Francisco | California | 248 | $277 million |
| The Johns Hopkins University | Maryland | 230 | $276 million |
| The Trustees of Columbia University in the City of New York | New York | 188 | $226 million |
| Regents of the University of Michigan | Michigan | 179 | $221 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PAR-21-114 still open?
No. It closed on April 5, 2024.
Who can apply for NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Pre-Clinical Research (R44 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Pre-Clinical Research (R44 Clinical Trial Not Allowed)?
Closed April 5, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under PAR-21-114?
NIH RePORTER lists 5 projects funded under PAR-21-114 in fiscal 2022 to 2026, at 5 institutions. The most were at Biocircuit Technologies, Inc., Myogene Bio, LLC, Amplo Biotechnology, Inc.
Who has won Extramural Research Programs in the Neurosciences and Neurological Disorders grants before?
The largest recipients over five fiscal years were The General Hospital Corporation, The Regents of the University of California, San Francisco, The Johns Hopkins University. The program made 8,641 awards worth $9.1 billion in that time.
Similar open grants
- Small Business Transition Grant for New Entrepreneurs (Parent R43/R44 Clinical Trial Optional)
- NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
- Successor-in-Interest (Type 6 Parent Clinical Trial Optional)
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)